Subtype specific elevated expression of Hyaluronidase-1 (HYAL-1) in Epithelial ovarian cancer

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Yoffou, Paule Héléna ^a   Edjekouane, Lydia ^a   Meunier, Liliane ^c   Tremblay, André ^b,d   Provencher, Diane Michèle ^b,c   Mes Masson, Anne Marie ^b,c   Carmona, Euridice ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HYALURONIDASE; HYALURONIDASE 1; MESSENGER RNA; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA, HUMAN; HYALURONOGLUCOSAMINIDASE; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE REPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; BLOOD; CLASSIFICATION; COLLOID CARCINOMA; CULTURE MEDIUM; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYALURONOGLUCOSAMINIDASE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79958713681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020705     Document Type: Article

References (80)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Liu CM, (2005) Cancer of the ovary. N Eng J Med 352: 1268-1269.
3. Cho KR, Shih IeM, (2009) Ovarian cancer. Annu Rev Pathol 4: 287-313.
4. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, et al. (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23: 41-44.
5. Hoglund M, Gisselsson D, Hansen GB, Sall T, Mitelman F, (2003) Ovarian carcinoma develops through multiple modes of chromosomal evolution. Cancer Res 63: 3378-3385.
6. Manderson EN, Mes-Masson AM, Novak J, Lee PD, Provencher D, et al. (2002) Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res 12: 112-121.
7. Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, et al. (2008) Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 47: 56-65.
8. Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, et al. (2004) Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 23: 5719-5728.
9. Csoka AB, Frost GI, Stern R, (2001) The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 20: 499-508.
10. Kim E, Baba D, Kimura M, Yamashita M, Kashiwabara S, et al. (2005) Identification of a hyaluronidase, Hyal5, involved in penetration of mouse sperm through cumulus mass. Proc Natl Acad Sci U S A 102: 18028-18033.
11. Csoka AB, Scherer SW, Stern R, (1999) Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31. Genomics 60: 356-361.
12. Martin-DeLeon PA, (2006) Epididymal SPAM1 and its impact on sperm function. Mol Cell Endocrinol 250: 114-121.
13. Stern R, Asari AA, Sugahara KN, (2006) Hyaluronan fragments: an information-rich system. Eur J Cell Biol 85: 699-715.
14. Hemming R, Martin DC, Slominski E, Nagy JL, Halayko AJ, et al. (2008) Mouse Hyal-3 encodes a 45-56 kDa glycoprotein whose overexpression increases hyaluronidase 1 activity in cultured cells. Glycobiology 18: 280-289.
15. Tuhkanen H, Anttila M, Kosma VM, Yla-Herttuala S, Heinonen S, et al. (2004) A Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer 109: 247-252.
16. Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH, et al. (2009) Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer 9: 143.
17. Hiltunen EL, Antilla M, Kultti A, Ropponen K, Penttinen J, et al. (2002) Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res 62: 6410-6413.
18. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, et al. (2000) High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60: 150-155.
19. Bourguignon LY, (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signalling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18: 251-259.
20. Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, et al. (2003) Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 106: 438-445.
21. Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, et al. (2000) Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 163: 348-356.
22. Lokeshwar VB, Selzer MG, (2008) Hyaluronidase: both a tumor promoter and suppressor. Review. Semin Cancer Biol 18: 281-287.
23. Delpech B, Laquerriere A, Maingonnat C, Bertrand P, (2002) Freger P. Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res 22: 2423-2427.
24. Wang X-Y, Tan J-X, Vasse M, Delpech B, Ren G-S, (2009) Comparison of hyaluronidase expression, invasiveness and tubule formation in ER(-) and ER(+) breast cancer cell lines in vitro. Chin Med J (Engl) 122: 1300-1304.
25. Lin G, Stern R, (2001) Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling. Cancer Lett 163: 95-101.
26. Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL, (2005) HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 65: 7782-7789.
27. Lokeshwar VB, Cerwinka WH, Lokeshwar BL, (2005) HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res 65: 2243-2250.
28. Takahashi Y, Li L, Kamiryo M, Asteriou T, Moustakas A, et al. (2005) Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GRO1-dependent manner. J Biol Chem 280: 24195-24204.
29. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, et al. (1994) Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 215: 303-309.
30. Provencher DM, Lounis H, Champoux L, Tétrault M, Manderson EN, et al. (2000) Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: 357-361.
31. Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, et al. (2008) Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer 8: 152.
32. Manderson EN, Mes-Masson AM, Novak J, Lee PD, Provencher D, et al. (2002) Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Research 12: 112-121.
33. Walton TJ, Li G, McCulloch TA, Seth R, Powe DG, et al. (2009) Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue. The Prostate 69: 810-819.
34. Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, et al. (2005) Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 24: 4672-4687.
35. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, et al. (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11: 321-333.
36. Ghosh MG, Thompson DA, Weigel RJ, (2000) PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 60: 6367-6375.
37. Mori K, Fujii R, Kida N, Takahashi H, Ohkubo S, et al. (1990) Complete primary structure of the human estrogen-responsive gene (pS2) product. J Biochem 107: 73-76.
38. Orimoto AM, Dumaresq-Doiron K, Jiang JY, Tanphaichitr N, Tsang BK, et al. (2008) Mammalian hyaluronidase induces ovarian granulosa cell apoptosis and is involved in follicular atresia. Endocrinology 149: 5835-5847.
39. Reissig JL, Strominger JL, Leloir LF, (1955) A modified colorimetric method for the estimation of N-acetylamino sugars. J Biol Chem 217: 959-966.
40. Sharma R, Mahadeswaraswamy YH, Harish Kumar K, Devaraja S, Kemparaju K, et al. (2009) Effect of anticoagulants on the plasma hyaluronidase activities. J Clin Lab Anal 23: 29-33.
41. Sanchez M, Sauvé K, Picard N, Tremblay A, (2007) The hormonal response of estrogen receptor beta is decreased by the phosphatidylinositol 3- kinase/Akt pathway via a phosphorylation-dependent release of CREB-binding protein. J Biol Chem 282: 4830-4840.
42. Sauvé K, Lepage J, Sanchez M, Heveker N, Tremblay A, (2009) Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 69: 5793-5800.
43. De Salegui M, Pigman W, (1967) The existence of an acid-active hyaluronidase in serum. Arch Biochem Biophys 120: 60-67.
44. Fiszer-Szafarz B, Szafarz D, Vannier P, (1990) Polymorphism of hyaluronidase in serum from man, various mouse strains and other vertebrate species revealed by electrophoresis. Biol Cell 68: 95-100.
45. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC, (2002) Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94: 32-38.
46. Greer JB, Modugno F, Allen GO, Ness RB, (2005) Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol 105: 731-740.
47. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, et al. (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288: 334-341.
48. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O, (2009) Hormone therapy and ovarian cancer. JAMA 302: 298-305.
49. Lee P, Rosen DG, Zhu C, Silva EG, Liu J, (2005) Expression of progesterone receptor is a favourable prognostic marker in ovarian cancer. Gynecol Oncol 96: 671-677.
50. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, et al. (2008) Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 111: 144-151.
51. Ho SM, (2003) Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1: 73.
52. Chen GG, Zeng Q, Tse GM, (2008) Estrogen and its receptors in cancer. Med Res Rev 28: 954-974.
53. Buchynska LG, Iurchenko NP, Grinkevych VM, Nesina IP, Chekhun SV, et al. (2009) Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Exp Oncol 31: 48-51.
54. Feeley KM, Wells M, (2001) Precursor lesions of ovarian epithelial malignancy. Histopathology 38: 87-95.
55. Aunoble B, Sanches R, Didier E, Bignon YJ, (2000) Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol 16: 567-76.
56. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, et al. (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589.
57. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, et al. (2006) Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecologic Oncology 102: 285-291.
58. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, et al. (2004) Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22: 1040-1044.
59. Trimble EL, Fountain J, Birrer MJ, (2006) Recommendations of the 2005 Ovarian Cancer State of the Science Meeting. Gynecologic Oncology 103: S26.
60. Meyer T, Rustin GJ, (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 9: 1535-1538.
61. Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, et al. (1992) Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer 4: 58-68.
62. Mertens F, Johansson B, Hoglund M, Mitelman F, (1997) Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 57: 2765-2780.
63. Tse C, Xiang RH, Bracht T, Naylor SL, (2002) Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res 62: 542-546.
64. Xiang R, Davalos AR, Hensel CH, Zhou XJ, Tse C, et al. (2002) Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res 62: 2637-2643.
65. van der Weyden L, Adams DJ, (2007) The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 1776: 58-85.
66. Donninger H, Vos MD, Clark GJ, (2007) The RASSF1A tumor suppressor. J Cell Sci 120: 3163-3172.
67. Gilks CB, Prat J, (2009) Ovarian carcinoma pathology and genetics: recent advances. Human Pathology 40: 1213-1223.
68. Toole BP, Slomiany MG, (2008) Hyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 18: 244-250.
69. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, et al. (2008) Hyaluronan in human tumors: Pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 18: 288-295.
70. Stern R, (2008) Association between cancer and "mucopolysaccharides": An old concept comes of age, finally. Semin Cancer Biol 18: 238-243.
71. Fiszer-Szafarz B, Vannier P, Lityńska A, Zou L, Czartoryska B, et al. (1995) Hyaluronidase in human somatic tissues and urine: polymorphism and the activity in diseases. Acta Biochim Pol 42: 31-33.
72. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, et al. (2006) From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 118: 1750-1758.
73. Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, et al. (2008) BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17: 913-920.
74. Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK, (2001) Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172: 213-222.
75. Choi JH, Wong AS, Huang HF, Leung P, (2007) Gonadotropins and ovarian cancer. Endocr Rev 28: 440-461.
76. Huhtaniemi I, (2010) Are gonadotrophins tumorigenic-A critical review of clinical and experimental data. Mol Cell Endocrinol 329: 56-61.
77. Soslow RA, (2008) Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27: 161-174.
78. Yamashita H, (2008) Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol 13: 380-383.
79. Tan JX, Wang XY, Li HY, Su XL, Wang L, et al. (2011) HYAL1 over-expression is correlated with the malignant behavior of human breast cancer. Int J Cancer 128: 1303-1315.
80. Bourguignon LY, Gilad E, Rothman K, Peyrollier K, (2005) Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. J Biol Chem 280: 11961-11972.